Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submitted-evidence log — page 3

Third-party data submitted to the Institute, what was submitted, by whom, and whether it was used. Data submitted and not used are recorded with the reason.

Submissions

74 documents · page 3 of 3

Table 1. Evidence submissions on this page, in date order.

ReferenceReceivedWhat was submittedConcerningSubmitted byOutcome
CEI-SE/03128 Sep 2023Certificate of analysisA supplier-issued certificate, submitted for assessment against the minimum data standard.TeduglutideDr Séverin ErlingssonNot used — could not be de-identified
CEI-SE/05505 Sep 2023Batch documentationManufacturing or release documentation for a named batch.LixisenatideDr Thaddeus Glendinning-UcheUsed — cited in a document
CEI-SE/01828 Aug 2023Regulatory assessment documentA published review document from a competent authority.SemaglutideDr Yehudit Norrington-BhattUsed — informed an assessment without citation
CEI-SE/05722 Aug 2023Correspondence with a supplierA documented exchange bearing on a dossier.Semaglutide, oralFlorentin JerninghamNot used — provenance not establishable
CEI-SE/00807 Aug 2023Certificate of analysisA supplier-issued certificate, submitted for assessment against the minimum data standard.ExenatideDr Ciarán Jankowiak-OseiNot used — could not be de-identified
CEI-SE/02320 Jul 2023Batch documentationManufacturing or release documentation for a named batch.Kisspeptin-10Dr Hamish AchterbergUnder assessment
CEI-SE/04016 Jul 2023Regulatory assessment documentA published review document from a competent authority.PT-141 (bremelanotide)Dr Clementine YlönenUnder assessment
CEI-SE/04721 Jun 2023Correspondence with a supplierA documented exchange bearing on a dossier.CagrilintideDr Nkechi VasconcelosUnder assessment
CEI-SE/00912 Jun 2023Third-party analytical reportA certificate or report from an independent laboratory.IGF-1 LR3Dr Yehudit Norrington-BhattUsed — informed an assessment without citation
CEI-SE/06204 Jun 2023Batch documentationManufacturing or release documentation for a named batch.MazdutideBenedikt HollingworthUsed — cited in a document
CEI-SE/01225 May 2023Third-party analytical reportA certificate or report from an independent laboratory.SS-31 (elamipretide)Dr Henrike Møllerup-AdeyemiUsed — informed an assessment without citation
CEI-SE/07422 May 2023Third-party analytical reportA certificate or report from an independent laboratory.RetatrutideUlysses UbertiniNot used — outside scope
CEI-SE/01520 May 2023Unpublished trial dataData from a trial not fully reported in the literature.SurvodutideDr Vasilisa Palmgren-KofiUsed — cited in a document
CEI-SE/03803 Apr 2023Correspondence with a supplierA documented exchange bearing on a dossier.DulaglutideDr Theodora QuennevilleNot used — outside scope
Contributors consented to publication at the point of submission. The Institute publishes no submission from a person who did not consent to be named.

page 3 of 3

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.